Brief: Pacira Signs Exclusive License With AmacaThera For Long-Acting Analgesic For Postsurgical Pain Relief
04/11/2025 12:33
Nov 4 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ENTERS EXCLUSIVE LICENSE AGREEMENT WITH AMACATHERA FOR ITS NOVEL LONG-ACTING ANALGESIC FOR POSTSURGICAL PAIN CONTROL PACIRA BIOSCIENCES INC - AMACATHERA TO RECEIVE $5 MILLION UPFRONT PAYMENT PACIRA BIOSCIENCES INC - PHASE 2 PROGRAM FOR AMT-143 EXPECTED TO BEGIN IN 2026 Source text: ID:nGNXbqfk3w Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees